Stealth Biotherapeutics Introduces Mito Assist Program for Patient Support
Stealth BioTherapeutics announced the launch of its Mito Assist Patient Support Program for access to FORZINITY injection. FORZINITY was granted accelerated approval by the U.S. FDA on September 19, 2025 as the first treatment for Barth syndrome, to improve muscle strength in adult and pediatric patients weighing at least 30 kilograms. As part of this initiative, Stealth has selected AnovoRx Specialty Pharmacy as its exclusive commercial distribution partner for FORZINITY in the United States. Through this partnership, AnovoRx will play a key role in helping patients, caregivers, and healthcare providers navigate the insurance coverage and access process.
